-
Media Release
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
-
Media Release
Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years
-
Media Release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
-
Media Release
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
-
Media Release
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
-
Media Release
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
-
Media Release
Novartis named first-ever corporate pharmaceutical partner of the National Football League
-
Media Release
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
-
Media Release
Early detection is a game changer: Novartis makes bold play to prioritize breast health and inspire a new wave of breast cancer screenings
-
Media Release
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
-
Media Release
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
-
Media Release
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS